Do SSRIs lower the risk of long COVID?
In a recent study posted to the medRxiv* preprint server, researchers conducted a retrospective study to determine whether selective serotonin reuptake inhibitors (SSRI) with immunomodulatory and antiplatelet properties can decrease the risk of post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC). Study: Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19. Image Credit: […]
Continue reading »